II. Indications
III. Dosing: Hyperprolactinemia
- Bromocriptine (Parlodel)
- Larger safety database than Cabergoline (preferred in women trying to conceive)
- Start: 1.25 to 2.5 mg at bedtime
- Titrate: Increase by 2.5 mg every 3-7 days up to 15 mg daily
- Cabergoline (Dostinex)
- Fewer side effects than Bromocriptine
- Start: 0.25 orally twice weekly
- Titrate: Increase by 0.25 mg every month up to 1 mg twice daily
IV. Dosing: Diabetes Mellitus 2
- Bromocriptine QR or Cycloset
- Adjunctive with Metformin (and other Oral Hypoglycemic agents)
- Dosing
- Start 0.8 mg each am
- May increase up to weekly by 0.8 mg/day, to a maximum of 4.8 mg daily
- Efficacy
- May lower Hemoglobin A1C 0.7 to 1.4%
- References
- Joe Weidner, MD (2018) email communication, received 11/10/2018
- Gardner (2013) Endocr Pract 19(1):100-6 +PMID:23337160 [PubMed]
- Chamarthi (2017) Postgrad Med 129(4):446-455 +PMID:28374645 [PubMed]
V. Adverse Effects
- Nausea or Vomiting
- Postural Hypotension
- Dizziness
- Headache
- Sedation
- Valvular disorders
- Reported with high dose Cabergoline (>4 mg daily)
VI. References
Images: Related links to external sites (from Bing)
Related Studies (from Trip Database) Open in New Window
| bromocriptine (on 5/17/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| BROMOCRIPTINE 2.5 MG TABLET | Generic | $2.89 each |
| BROMOCRIPTINE 5 MG CAPSULE | Generic | $6.12 each |
| cabergoline (on 5/17/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| CABERGOLINE 0.5 MG TABLET | Generic | $7.84 each |
Ontology: Parlodel (C0000266)
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | D001971 |
| English | parlodel, Parlodel |
Ontology: Bromocriptine (C0006230)
| Definition (NCI) | A semisynthetic, ergot alkaloid with antiparkinson and lactation inhibitory activities. Bromocriptine selectively binds to and activates the postsynaptic dopamine D2-like receptors in the corpus striatum of the central nervous system (CNS). D2-like receptors are coupled to inhibitory G-proteins, which inhibit adenylyl cyclase, thereby preventing signal transduction mediated via cAMP and leading to an inhibitory effect on neurotransmission. This improves Parkinson symptoms, such as dyskinesia. Bromocriptine also has an inhibitory effect on the anterior pituitary gland, which results in blockage of prolactin secretion, thereby suppressing lactation. |
| Definition (CSP) | D2 dopamine agonist used as a prolactin inhibitor. |
| Definition (MSH) | A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. |
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | D001971 |
| SnomedCT | 323134006, 325986001, 325985002, 116656002, 387039007, 46293006 |
| LNC | LP15165-1, MTHU002554 |
| English | 2 Bromoergocryptine, 2-Bromoergocryptine, 2-Bromoergokryptine, Bromocriptin, Bromocriptine, Bromocryptin, 2 Bromoergokryptine, 2 Bromo alpha ergocryptine, 2 Bromo alpha ergokryptine, 2-Bromo-alpha-ergocryptine, 2-Bromo-alpha-ergokryptine, Bromocriptine [endocrine], BROMOERGOCRYPTINE 02, Bromocriptine [endocrine use], Bromocriptine [parkinsons], Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'alpha)-, BROMOCRIPTINE, Bromocriptine [Chemical/Ingredient], bromocriptin, bromocryptin, bromocryptine, Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2-methylpropyl)-, Bromocriptine [parkinsons] (product), Bromocriptine [endocrine use] (product), Bromocriptine [endocrine] (product), bromocriptine, 2-Br-alpha-ergocryptine, Brom-ergocryptine, Bromocryptine, Bromocriptine (product), Bromocriptine (substance), BRCR, Bromocriptine [endocrine use] (substance), Bromocriptine [endocrine] (substance), Bromocriptine [parkinsons] (substance) |
| Swedish | Bromokriptin |
| Czech | bromokriptin |
| Finnish | Bromokryptiini |
| Italian | 2-Bromoergocriptina, 2-Bromo-alfa-ergocriptina, Bromocriptina |
| Russian | 2-BROMOERGOKRIPTIN, BROMOKRIPTIN, PARLODEL, 2-БРОМОЭРГОКРИПТИН, БРОМОКРИПТИН, ПАРЛОДЕЛ |
| German | BROMERGOCRYPTIN 02, 2-Bromergocryptin, Bromocriptin, Bromocryptin |
| Croatian | BROMOKRIPTIN |
| Polish | Bromokryptyna |
| Japanese | ブロモクリプチン, 2-ブロモエルゴクリプチン |
| Spanish | bromocriptina [endocrina] (producto), bromocriptina [uso endocrino], bromocriptina [endocrina], bromocriptina [antiparkinsoniano], bromocriptina [uso endocrino] (producto), bromocriptina [antiparkinsoniano] (producto), 2-br-alfa-ergocriptina, 2-bromoergocriptina, brom-ergocriptina, bromocriptina (producto), bromocriptina (sustancia), bromocriptina, 2-Bromoergocriptina, Bromocriptina |
| French | Bromocriptine |
| Portuguese | 2-Bromoergocriptina, Bromocriptina |
Ontology: cabergoline (C0107994)
| Definition (NCI) | A synthetic ergoline derivative and a long-acting dopamine receptor agonist with high affinity for the dopamine D2 receptor. Cabergoline exerts an inhibitory effect on prolactin secretion by acting on dopamine receptors present in pituitary lactotrophs. This drug also binds to dopamine D2 receptors in the corpus striatum, thereby mimicking the actions of dopamine on motor control. Cabergoline also possesses antioxidant and neuroprotective properties due to its free radical scavenging activity. Cabergoline is used in the treatment of Parkinson's disease and in the treatment of hyperprolactinemia. |
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | C047047 |
| SnomedCT | 323191001, 109139002, 386979007 |
| English | cabergoline, 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea, Cabergoline [parkinsons], cabergoline (medication), dopamine agonists cabergoline, 1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea, CABERGOLINE, cabergoline [Chemical/Ingredient], cabergoline parkinsons, Cabergoline [parkinsons] (product), Cabergoline, Cabergoline (product), Cabergoline (substance), Cabergoline [parkinsons] (substance) |
| Spanish | cabergolina [antiparkinsonianos] (producto), cabergolina [antiparkinsonianos], cabergolina (producto), cabergolina (sustancia), cabergolina |
Ontology: Dostinex (C0526034)
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | C047047 |
| English | Dostinex, Cabaseril, Pfizer brand of cabergoline, cabaser, dostinex, Cabaser |
